A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
|ClinicalTrials.gov Identifier: NCT00004581|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : February 20, 2009
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Lopinavir/Ritonavir Drug: Nevirapine||Phase 3|
Patients receive 1 of the following:
- ABT-378/RTV plus NVP plus 2 NRTIs; or
- Investigator-selected PI(s) plus NVP plus 2 NRTIs.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||300 participants|
|Official Title:||A Randomized, Open-Label, Phase III Study of ABT-378/Ritonavir in Combination With Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination With Nevirapine and Two NRTIs in Antiretroviral-Experienced HIV-Infected Subjects|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004581
Show 88 Study Locations